JACC:射血分数对心衰患者预后是否有影响?

2017-11-15 MedSci MedSci原创

心衰患者预后差,并且可根据射血分数来分类。本研究的目的旨在评估住院心衰患者伴保留型射血分数(HFpEF) (EF ≥50%)、心衰患者伴边缘型射血分数(HFbEF) (EF 41% - 49%)和心衰患者伴减少型射血分数(HFrEF) (EF ≤40%)预后结局的差异。本研究共纳入2005年至2009年来自254家医院被诊断为心衰的39982名患者,其中,18299名患者 (46%) 为HFpEF

心衰患者预后差,并且可根据射血分数来分类。

本研究的目的旨在评估住院心衰患者伴保留型射血分数(HFpEF) (EF ≥50%)、心衰患者伴边缘型射血分数(HFbEF) (EF 41% - 49%)和心衰患者伴减少型射血分数(HFrEF) (EF ≤40%)预后结局的差异。

本研究共纳入2005年至2009年来自254家医院被诊断为心衰的39982名患者,其中,18299名患者 (46%) 为HFpEF,,3285名患者 (8.2%) 为HFbEF,18398名患者 (46%) 为HFrEF,总体平均生存时间为2.1年,风险调整生存分析后,三组患者的5年死亡率相似(HFrEF 75.3% vs. HFpEF 75.7%;HR: 0.99 [95% Cl: 0.958 - 1.022]; HFbEF 75.7% vs. HFpEF 75.7%; HR: 0.99 [95% Cl: 0.947 - 1.046]),复合死亡率和再住院率在各亚组中也无明显差异。心源性和心衰再住院率在HFrEF 和HFbEF患者中更高。此外,与美国正常人群相比,所有年龄段和射血分数亚组的心衰患者生存时间更低。

研究结果显示,在住院的心衰患者中,各射血分数亚组患者的5年生存率相似,心源性和心衰再住院率均升高。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1691941, encodeId=6c0e1691941b1, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri May 11 10:51:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853846, encodeId=80a318538467b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 08 01:51:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325603, encodeId=4586132560397, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 17 07:51:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373374, encodeId=599913e337452, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Nov 17 07:51:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1691941, encodeId=6c0e1691941b1, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri May 11 10:51:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853846, encodeId=80a318538467b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 08 01:51:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325603, encodeId=4586132560397, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 17 07:51:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373374, encodeId=599913e337452, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Nov 17 07:51:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2018-06-08 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1691941, encodeId=6c0e1691941b1, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri May 11 10:51:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853846, encodeId=80a318538467b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 08 01:51:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325603, encodeId=4586132560397, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 17 07:51:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373374, encodeId=599913e337452, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Nov 17 07:51:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1691941, encodeId=6c0e1691941b1, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri May 11 10:51:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853846, encodeId=80a318538467b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 08 01:51:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325603, encodeId=4586132560397, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 17 07:51:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373374, encodeId=599913e337452, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Nov 17 07:51:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]

相关资讯

CIRC RES:iPSCs胞外囊泡修复心肌更加有效和安全

细胞外囊泡(EVs)是细胞以出芽方式或者外分泌方式形成的一种膜状小体。由诱导多能干细胞(iPSCs)分泌的EVs产生的心肌修复能力与iPSCs直接相比是否存在优势尚未阐明。本研究的目的旨在评估iPSCs分泌的Evs在体外对心肌细胞生物学功能的影响,以及通过体内实验比较iPSCs与iPSCs分泌的EVs在心肌修复能力上的差异。本研究通过连续离心的方法对小鼠的iPSCs的Evs进行提取,通过原子力显微

Circulation:服用钠葡萄糖协同转运蛋白2抑制剂的心血管结局和风险!

在这个高风险人群中,服用SGLT2i与较低的ACM、HHF和MACE以及较高的BKA风险相关。该研究结果强调了服用SGLT2i潜在的好处和风险。目前尚不清楚的是,BKA风险是否可以扩大到这类药物,因为该研究不足以对个体之间的治疗进行比较。

JAHA:血浆总胆红素与高血压相关性研究

循环血液中的总胆红素水平与心血管疾病发生风险的升高呈独立相关性。然而,循环血液中的总胆红素水平与高血压的关系尚未阐明。本研究纳入了PREVEND临床试验中的3989名无高血压的研究对象,并对其基线的血浆总胆红素水平进行了检测。结果发现,经过平均10.7年时间的随访,共有1206名新发的高血压患者,并且基线的血浆总胆红素水平与高血压发生的风险基本呈对数相关性,血浆总胆红素的log值每升高一个SD,年

JAHA:奈比洛尔在血管保护功能方面更胜一筹

血管内皮纤维蛋白溶解功能在高血压患者中受损是其致动脉粥样硬化形成的机制之一。目前,β受体阻滞剂对内皮纤维蛋白溶解功能的影响尚属未知。本研究的目的旨在比较评估奈比洛尔和美托洛尔的慢性治疗对血压升高成年人的内皮组织型纤溶酶原激活剂(t-PA)释放的影响。本次随机双盲对照研究纳入了44例(女性占36%)中年研究对象,随机分成奈比洛尔(5 mg/d)治疗组、美托洛尔(100 mg/d)治疗组和安慰剂组。在

JACC:心血管疾病风险评分——FBS vs ICHS评分

理想心血管健康评分(ICHS)被推荐用来心血管疾病的初级预防,其他一些不需要实验室检查的更简单的工具比如福斯特BEWAT(血压[B]、运动[E]、体重[W]、营养[A]和吸烟情况[T])评分(FBS)同样也适用于初级预防评估。本研究的目的旨在比较和评估ICHS和FBS在亚临床动脉粥样硬化方面的有效性。本研究纳入了3983例40-54岁的研究对象,亚临床动脉粥样硬化通过对其左右颈动脉、腹主动脉、左右

JAMA Cardiology:对 50 万中国人 7 年追踪研究:体力活动可降低心血管病风险

热爱马拉松的蓝领们也许会希望看到的一个好消息是:科学家们最新研究发现,体力劳动能帮助人们远离心脑血管疾病的困扰。